Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MyCiss Plus is an oral orthopedic nutritional supplement developed by Elbrit Life Sciences. It is formulated as a tablet containing a combination of Cissus quadrangularis extract, calcium phosphate, ergocalciferol (Vitamin D2), and Withania somnifera (Ashwagandha) extract. The supplement is designed to support bone and joint health, promote bone mineralization, accelerate fracture healing, and reduce joint pain. Cissus quadrangularis and Withania somnifera extracts provide osteogenic, anti-inflammatory, and chondroprotective effects, while calcium phosphate and ergocalciferol supply essential minerals and vitamins to enhance bone mineral density and prevent osteoporosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MyCiss Plus.